Prometic announces agreement to commercialize prion capture technology
ProMetic Life Sciences Inc. announced that it has entered into a collaboration agreement with Abraxis BioScience, Inc. to develop and commercialize various applications deriving from ProMetic's prion capture technology platform. As part of the Agreement, Abraxis and ProMetic will equally share in the cost for the development of such new applications as well as the financial rewards arising from their commercialization.
Due to the changing landscape surrounding prion transmission and the worldwide mounting interest in improving the safety profile of blood-derived therapeutics, both companies believe that this arrangement will allow them to more fully exploit ProMetic’s validated prion capture technology platform.
This Agreement is complementary to ProMetic’s outstanding commercial arrangements regarding the exploitation of its prion capture technology platform, such as those with MacoPharma SA for the commercialization of the P-Capt® prion capture filter and with Octapharma AG for OctaplasLG®, the only commercially available prion-reduced plasma for transfusion.
Other news from the department business & finance
